Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 4.6%

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) shares were down 4.6% during mid-day trading on Wednesday . The stock traded as low as $23.02 and last traded at $23.02. Approximately 52,063 shares traded hands during trading, a decline of 63% from the average daily volume of 141,196 shares. The stock had previously closed at $24.14.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on DNTH shares. Wedbush upped their price objective on Dianthus Therapeutics from $24.00 to $33.00 and gave the stock an "outperform" rating in a report on Friday, March 22nd. Jefferies Financial Group upped their price objective on Dianthus Therapeutics from $22.00 to $39.00 and gave the stock a "buy" rating in a report on Friday, March 22nd. Finally, Stifel Nicolaus started coverage on Dianthus Therapeutics in a report on Thursday, February 15th. They set a "buy" rating and a $44.00 price objective on the stock. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $37.00.

Dianthus Therapeutics Trading Down 3.3 %

The company has a fifty day moving average of $25.82 and a two-hundred day moving average of $17.11.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings results on Thursday, March 21st. The company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($1.11) by $0.40. The company had revenue of $0.46 million for the quarter, compared to analysts' expectations of $0.73 million. As a group, equities analysts forecast that Dianthus Therapeutics, Inc. will post -1.92 earnings per share for the current fiscal year.

Institutional Trading of Dianthus Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC purchased a new stake in Dianthus Therapeutics in the fourth quarter worth $25,000. Citigroup Inc. purchased a new stake in Dianthus Therapeutics in the third quarter worth $53,000. Dimensional Fund Advisors LP purchased a new stake in Dianthus Therapeutics in the fourth quarter worth $153,000. Northern Trust Corp purchased a new stake in Dianthus Therapeutics in the fourth quarter worth $159,000. Finally, Acadian Asset Management LLC purchased a new stake in Dianthus Therapeutics in the third quarter worth $303,000. Hedge funds and other institutional investors own 47.53% of the company's stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.